Interview of EORTC members about COVID-19 impact on cancer clinical trials

The COVID-19 pandemic has affected cancer clinical trials in many ways, creating challenges and new opportunities.

Recruitment of many studies slowed down, patients did not dare to go to the hospital due to the fear of infection and mobility limitations as shortage of research staff.

During the pandemic, clinical investigators had to adapt quickly to continue the follow-up of their patients by setting remote monitoring, remote dispensation of medications for patients, telematics clinical visits, etc.

Our members share their stories on the impact of the pandemic and how they overcame the challenges, which resulted in being beneficial to patients.

Watch the interviews of our members:


Prof. Josep Tabernero, Vall d’Hebron University Hospital & Vall d’Hebron Institute of Oncology, Barcelona, Spain


Prof. Yolande Lievens, UZ Ghent, Belgium


Prof. Piotr Rutkowski, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland


Prof. Kristin Bjordal, University of Oslo, Norway


Prof. Jean-Yves Blay, Centre Léon Bérard, Lyon, France

Back to news list

Related News

  • Clinical Trials Day 2024: a Q&A on pragmatic clinical trials

  • EORTC/EMA workshop suggests an international way forward for treatment optimisation studies

  • EORTC’s Participation at the ESTRO Congress 2024

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023

  • EORTC Quality of Life measures integrated in CDISC